Skip to main content
OpenTrials
Completed

NCT Number: NCT05286671

Evaluation of Perioperative Management of Curative Anticoagulants in the Geriatric Perioperative Unit in Patient Hospitalized for Femoral Neck Fracture.

Pilot study to evaluate the management of curative anticoagulant prescriptions pre- and postoperatively in elderly patients hospitalized for femoral neck fracture.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anticoagulants; Circulating, Hemorrhagic Disorder Femoral Fractures Femoral Neck Fractures Fractures, Bone Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hip Fractures Hip Injuries Leg Injuries Wounds and Injuries

Age range

75 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Nimes

Nîmes, 30029, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient 75 years or older
  • Hospitalized in the geriatric perioperative unit for a femoral neck fracture between 18/11/2019 and 30/06/2021
  • Treated with a curative anticoagulant at entry
  • Patient enrolled in or receiving a social security plan

Exclusion criteria

  • Orthopedic patient housed in the geriatric perioperative unit
  • Patient who objected to the use of their data

Treatment and study plan

Primary outcomes

  1. Rate of compliance with the recommendations for direct oral anticoagulants (DOAC)..

    Time frame: Day 0

    Rate of compliance with the french working group on perioperative haemostasis (GIHP) recommendations for DOACrecommendations for DOA.

  2. Rate of compliance with the recommendations for vitamin K antagonists (VKA).

    Time frame: Day 0

    Rate of compliance with the french health authority (HAS) recommendations for VKA

Secondary outcomes

  1. Number of pharmaceutical interventions

    Time frame: Day 0

    Number of pharmaceutical interventions regarding anticoagulant prescriptions

  2. description of pharmaceutical interventions

    Time frame: Day 0

    description of pharmaceutical interventions

  3. Evaluation of the morbi-mortality

    Time frame: Day 0

    Mortality, re-hospitalizations at 30 days, characterization of bleeding complications, characterization of thrombotic complications

  4. Description of the evolution of the plasma dosage of DOAC and the international normalized ratio (INR) and analysis of the operative delay

    Time frame: Day 0

    Value of preoperative DOAC plasma dosage, value of INR dosage pre- and post-op, analysis of the operative delay

  5. description of the population

    Time frame: Day 0

    age, weight, height, body mass index, comorbidities

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Acronym: ANTICOGER

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Mar 18, 2022
Registry last updated
Apr 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.